
Sign up to save your podcasts
Or
Hydroxychloroquine has evolved from a sleepy anti-malaria drug into a partisan litmus test over the future of COVID-19 treatment. Dan and Axios healthcare reporter Bob Herman dig into what we know about the drug, what we still don't, and why both matter.
PLUS: New money for small businesses and a way to help New York medical workers
4.3
690690 ratings
Hydroxychloroquine has evolved from a sleepy anti-malaria drug into a partisan litmus test over the future of COVID-19 treatment. Dan and Axios healthcare reporter Bob Herman dig into what we know about the drug, what we still don't, and why both matter.
PLUS: New money for small businesses and a way to help New York medical workers
1,639 Listeners
4,330 Listeners
1,745 Listeners
8,639 Listeners
3,459 Listeners
111,310 Listeners
55,941 Listeners
2,274 Listeners
5,417 Listeners
5,912 Listeners
2,949 Listeners
2,021 Listeners
15,240 Listeners
4,367 Listeners
155 Listeners
1,147 Listeners
403 Listeners